Who We Are
Pioneering the Future of Cancer Care
We’re an essential partner to patients, physicians, researchers, and biopharma organizations navigating the complex landscape of cancer care. Our genomic insights help guide informed decisions about treatment plans and research priorities.
Over the past decade, we’ve partnered with researchers, biopharma, advocacy organizations, government bodies, health plans, and regulators to validate the use of genomic testing in clinical care, drive awareness among patients and physicians and ultimately support broader access for patients.
The answers we provide through our testing are essential first steps in developing informed treatment strategies and accelerating the development of transformative new therapies.
Diversity, Equity and Inclusion
At Foundation Medicine, we believe that transforming cancer care requires a company culture where diversity, equity and inclusion (DE&I) is prioritized.
Our Diversity, Equity and Inclusion Report
Foundation Medicine’s inaugural DE&I report spotlights our work to evolve forward-looking and integrated DE&I initiatives and our commitment to eliminating healthcare disparities, with a focus on our efforts in 2021. The report highlights our workforce diversity numbers and shares the voices of our employees and executives. From our research to our collaborations, from the lab to our advocacy efforts, our internal commitment to DE&I is as important as our external commitment to our partners, physicians, and patients.
Our Passion is Personal.
What We Do
An Ecosystem of Care
Collaborating to Move Cancer Care Forward
We believe every patient living with advanced cancer should benefit from comprehensive genomic information to inform their care. That’s why we’ve built a powerful portfolio of comprehensive genomic profiling (CGP) tests that—via both blood and tissue samples—evaluate more than 300 genes known to drive cancer.
Better Care Today
Support Services: Offering financial assistance for qualifying patients, decision support tools, and more
Genomic Testing with Actionable Options: Offering a proven portfolio of comprehensive genomic profiling tests to deliver insights across a broad range of cancer types
Personalized Treatment Decisions: Matching patients to targeted therapies, immunotherapies, and clinical trial options
Better Care Tomorrow
Clinical Trial Design, Support and Screening: Helping biopharma run faster, more efficient trials
Data Analysis Tools: Uncovering new insights to help accelerate biomarker research and drug development
Target Discovery and Market Launch Support: Partnering with the biopharma industry to help them discover, develop, and distribute the next breakthrough treatments for patients
Better Care Together
Partnerships: Collaborating with patient advocacy groups, the world’s leading medical centers, and researchers to transform cancer care
Molecular Data Research Initiatives: The precision of our tests goes beyond technology—we’re empowering researchers to generate new connections and insights that impact patient care
Patient Samples Profiled
Following the completion of the Human Genome Project and the launch of the Cancer Genome Atlas, Foundation Medicine’s founders envisioned a world where all cancer patients could benefit from genomic insights at the point of care, and that with a deeper, molecular-level understanding of this disease, we could fundamentally transform the way cancer is treated.
From this idea—democratizing the power of molecular information to benefit patients around the world—Foundation Medicine was born.
We know what’s next because, at Foundation Medicine, we’re the ones creating it.